Search Results

Orca Bio today announced that it has completed enrollment in the pivotal Precision-T Phase 3 clinical study.

The Precision-Panc team at the University of Glasgow, with their Co-Sponsor, NHS Greater Glasgow & Clyde, announced the opening of the Phase II PRIMUS-006 study evaluating IMM-101, a broad-spectrum immunomodulatory agent containing heat-killed, whole cell Mycobacterium obuense, in combination with gemcitabine and pembrolizumab as first-line treatment in patients with metastatic pancreatic cancer.

Prometheus Laboratories Inc. announced the execution of provider agreements with three large regional health plans to facilitate access to PredictrPK®, precision-guided biologic testing, and other Prometheus testing services to the participating health plans and their respective members.

Rymedi and Precision Genetics, two leading pioneers in healthcare technology solutions, proudly announce their strategic partnership aimed at transforming health outcomes and efficiencies through precision medicine. T

Precision BioSciences, Inc. today announced its addition to the Russell Microcap® Index.